Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

NovaBay Pharmaceuticals (NBY) Shares Outstanding (Weighted Average) (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed Shares Outstanding (Weighted Average) for 14 consecutive years, with $5.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 408.74% to $5.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $5.9 million, a 408.74% increase, with the full-year FY2024 number at $3.4 million, up 2730.0% from a year prior.
  • Shares Outstanding (Weighted Average) was $5.9 million for Q3 2025 at NovaBay Pharmaceuticals, up from $5.6 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $44.9 million in Q3 2021 to a low of $75000.0 in Q2 2023.
  • A 5-year average of $8.5 million and a median of $1.5 million in 2022 define the central range for Shares Outstanding (Weighted Average).
  • Peak YoY movement for Shares Outstanding (Weighted Average): crashed 96.63% in 2022, then soared 4323.33% in 2025.
  • NovaBay Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $1.2 million in 2021, then grew by 29.11% to $1.6 million in 2022, then plummeted by 92.55% to $120000.0 in 2023, then skyrocketed by 2730.0% to $3.4 million in 2024, then surged by 73.03% to $5.9 million in 2025.
  • Per Business Quant, the three most recent readings for NBY's Shares Outstanding (Weighted Average) are $5.9 million (Q3 2025), $5.6 million (Q2 2025), and $5.3 million (Q1 2025).